Twist Bioscience Corp (TWST) reported its Q3 2025 earnings, showing a significant 18% year-over-year increase in revenue, reaching $96.1 million. Despite this growth, the company’s stock saw a decline of 5.58% in premarket trading, with shares priced at $31.80. The stock has experienced significant volatility, with a beta of 2.42 and a 27.5% decline year-to-date according to InvestingPro data. This reaction comes as the company posted an adjusted EBITDA loss of $8 million, although this was an improvement from the previous fiscal year.
Key Takeaways
- Twist Bioscience’s revenue grew by 18% year-over-year, driven by strong performance in its NGS segment.
- The company improved its gross margin to 53.4%, up from 43.3% in the previous year.
- Despite revenue growth, Twist Bioscience reported an adjusted EBITDA loss of $8 million.
- Premarket trading saw the company’s stock fall by 5.58%.
Company Performance
Twist Bioscience showed robust performance in Q3 2025, with revenue reaching $96.1 million, marking an 18% increase from the same quarter last year. The company’s gross margin improved significantly to 53.4%, reflecting enhanced operational efficiencies and cost management. The NGS segment was a standout, with a 27% year-over-year growth, contributing $55.3 million to the total revenue. InvestingPro analysis shows the company maintains strong financial health with a current ratio of 4.51, indicating robust liquidity. Despite these gains, the company continues to face challenges in achieving profitability, as evidenced by the adjusted EBITDA loss.
Financial Highlights
- Revenue: $96.1 million, up 18% year-over-year
- Gross Margin: 53.4%, up from 43.3% in FY2024
- Synbio Revenue: $35.2 million, 7% YoY growth
- NGS Revenue: $55.3 million, 27% YoY growth
- Biopharma Services Revenue: $5.6 million, 10% YoY growth
- Adjusted EBITDA Loss: $8 million, improved by $14 million compared to FY2024
- Market Reaction
Following the earnings announcement, Twist Bioscience’s stock price dropped by 5.58% in premarket trading, settling at $31.80. This decline comes despite the company’s positive revenue growth and improved gross margins. According to InvestingPro, which offers 8 additional valuable insights about TWST, the stock has taken a significant hit over the last week, dropping 7.8%. The stock’s movement could reflect investor concerns over the continued adjusted EBITDA losses and the broader market sentiment towards biotech firms. InvestingPro’s comprehensive analysis indicates the stock is currently trading near its Fair Value.
Outlook & Guidance
Twist Bioscience provided guidance for the remainder of FY2025, projecting total revenue between $374 million and $376 million, which would represent a growth rate of approximately 19.7%. The company expects its gross margin to be in the range of 50.5% to 51%, with an adjusted EBITDA loss between $45 million and $47 million. Key growth areas include Synbio and NGS, with revenue guidance set at $144 million to $145 million and $267 million to $268 million, respectively.
Executive Commentary
CEO Emily Leproust highlighted the company’s innovative capabilities, stating, "We turned complexity into opportunity." President and COO Patrick Finn emphasized the competitive edge of Twist Bioscience’s technology, noting, "Our technology advantage gives us a product and a value proposition that resonates for the customer." These comments underscore the company’s strategic focus on leveraging its technology to drive growth and customer engagement.
Risks and Challenges
- Continued adjusted EBITDA losses could impact investor confidence.
- Market saturation in key segments like NGS might limit growth potential.
- Macroeconomic pressures and currency fluctuations could affect international sales.
- The competitive landscape in the biotech sector remains intense, requiring continuous innovation.
- During the earnings call, analysts inquired about the company’s strategies for sustaining growth in the Synbio and NGS markets. Management addressed these concerns by outlining plans for product innovation and expansion into new geographic markets. Additionally, questions were raised about the challenges in international markets, which the company acknowledged as a focus area for improvement.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.